Lipoprotein(a) as a therapeutic target in cardiovascular disease

Bibliography

• Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of CVD: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol 2012;60(8):716-21
   PubMed Web of Science ®Google Scholar
• Boffa MB, Koschinsky ML. Update on lipoprotein(a) as a cardiovascular risk factor and mediator. Curr Atheroscler Rep 2013;15(10):360-6
   PubMed Web of Science ®Google Scholar
• McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330(6144):132-7
   PubMed Web of Science ®Google Scholar
• Gabel BR, Koschinsky ML. Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). Biochemistry 1995;34(48):15777-84
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol 2003;14(4):361-6
   PubMed Web of Science ®Google Scholar
• Utermann G, Menzel HJ, Kraft HG, et al. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987;80(2):458-65
   PubMed Web of Science ®Google Scholar
• van der Hoek YY, Wittekoek ME, et al. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum Mol Genet 1993;2(4):361-6
   PubMed Web of Science ®Google Scholar
• Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993;2(7):933-40
   PubMed Web of Science ®Google Scholar
• Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 2004;37(5):333-43
   PubMed Web of Science ®Google Scholar
• Koschinsky ML, Marcovina SM. Lipoprotein(a). In: Ballantyne CM, editor. Clinical lipidology: a companion to braunwald’s heart disease. Saunders Elsevier, Philadelphia; 2009. p. 130-43
   Google Scholar
• Jacobson TA. Lipoprotein(a),cardiovascular disease, and contemporary management. Mayo Clin Proc 2013;88(11):1294-311
   PubMed Web of Science ®Google Scholar
• Trégouët DA, König IR, Erdmann J, et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009;41(3):283-5
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301(22):2331-9
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361(26):2518-28
   PubMed Web of Science ®Google Scholar
• Erqou S, Thompson A, Di Angelantonio E, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010;55(19):2160-7
   PubMed Web of Science ®Google Scholar
• Hopewell JC, Seedorf U, Farrall M, et al. Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med 2013; In press
   Web of Science ®Google Scholar
• IBC 50K CAD Consortium. Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genet 2011;7(9):e1002260
   Web of Science ®Google Scholar
• Nestel PJ, Barnes EH, Tonkin AM, et al. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler Thromb Vasc Biol 2013;33(12):2902-8
   PubMed Web of Science ®Google Scholar
• O’Donoghue M, Morrow DA, Tsimikas S, et al. Lipoprotein (a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol 2014;63(6):520-7
   PubMed Web of Science ®Google Scholar
• Maher VM, Brown BG, Marcovina SM, et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995;274(22):1771-4
   PubMed Web of Science ®Google Scholar
• Marburger C, Hambrecht R, Niebauer J, et al. Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men. Am J Cardiol 1994;73(11):742-6
   PubMed Web of Science ®Google Scholar
• Berg K, Dahlén G, Christophersen B, et al. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 1997;52(5):254-61
   PubMed Web of Science ®Google Scholar
• Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial. Circulation 2014;129(6):635-42
   PubMed Web of Science ®Google Scholar
• Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013;368(6):503-12
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014;63(5):470-7
   PubMed Web of Science ®Google Scholar
• Guerra R, Yu Z, Marcovina S, et al. Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study. Circulation 2005;111(12):1471-9
   PubMed Web of Science ®Google Scholar
• Erbel R, Lehmann N, Churzidse S, et al. Gender-specific association of coronary artery calcium and lipoprotein parameters: the Heinz Nixdorf Recall Study. Atherosclerosis 2013;229(2):531-40
   PubMed Web of Science ®Google Scholar
• Rader DJ, Cain W, Ikewaki K, et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994;93(6):2758-63
   PubMed Web of Science ®Google Scholar
• Utermann G. Genetic architecture and evolution of the lipoprotein(a) trait. Curr Opin Lipidol 1999;10(2):133-41
   PubMed Web of Science ®Google Scholar
• White AL, Guerra B, Lanford RE. Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum. J Biol Chem 1997;272(2):5048-55
   PubMedGoogle Scholar
• Becker L, Cook PM, Koschinsky ML. Identification of sequences in apolipoprotein(a) that maintain its closed conformation: a novel role for apo(a) isoform size in determining the efficiency of covalent Lp(a) formation. Biochemistry 2004;43(31):9978-88
   PubMed Web of Science ®Google Scholar
• Cain WJ, Millar JS, Himebauch AS, et al. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res 2005;46(12):2681-91
   PubMed Web of Science ®Google Scholar
• Kostner KM, Maurer G, Huber K, et al. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol 1996;16(8):905-11
   PubMed Web of Science ®Google Scholar
• Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism 2013;62(4):479-91
   PubMed Web of Science ®Google Scholar
• Rader DJ, Mann WA, Cain W, et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995;95(3):1403-8
   PubMed Web of Science ®Google Scholar
• Kraft HG, Lingenhel A, Raal FJ, et al. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20(2):522-8
   PubMed Web of Science ®Google Scholar
• Yang XP, Amar MJ, Vaisman B, et al. Scavenger receptor-BI is a receptor for lipoprotein(a). J Lipid Res 2013;54(9):2450-7
   PubMed Web of Science ®Google Scholar
• Grainger DJ, Kemp PR, Liu AC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994;370(6489):460-2
   PubMed Web of Science ®Google Scholar
• Qin SY, Liu J, Jiang HX, et al. Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: meta-analysis of 9 cohort studies. Atherosclerosis 2013;227(2):360-6
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol 2012;32(7):1732-41
   PubMed Web of Science ®Google Scholar
• Spence JD, Koschinsky M. Mechanisms of lipoprotein(a) pathogenicity: prothrombotic, proatherosclerotic, or both? Arterioscler Thromb Vasc Biol 2012;32(7):1550-1
   PubMed Web of Science ®Google Scholar
• Cho T, Jung Y, Koschinsky ML. Apolipoprotein(a), through its strong lysine-binding site in KIV(10), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem 2008;283(45):30503-12
   PubMed Web of Science ®Google Scholar
• Cho T, Romagnuolo R, Scipione C, et al. Apolipoprotein(a) stimulates nuclear translocation of β-catenin: a novel pathogenic mechanism for lipoprotein(a). Mol Biol Cell 2013;24(3):210-21
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005;353(1):46-57
   PubMed Web of Science ®Google Scholar
• Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 2008;49(10):2230-9
   PubMed Web of Science ®Google Scholar
• Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med 2011;5(5):673-94
   PubMed Web of Science ®Google Scholar
• Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab 2010;12(5):467-82
   PubMed Web of Science ®Google Scholar
• Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363(25):2406-15
   PubMed Web of Science ®Google Scholar
• Lambert G, Sjouke B, Choque B, et al. The PCSK9 decade. J Lipid Res 2012;53(12):2515-24
   PubMed Web of Science ®Google Scholar
• McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59(25):2344-53
   PubMed Web of Science ®Google Scholar
• Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012;60(19):1888-98
   PubMed Web of Science ®Google Scholar
• Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367(20):1891-900
   PubMed Web of Science ®Google Scholar
• Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012;126(20):2408-17
   PubMed Web of Science ®Google Scholar
• Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012;308(23):2497-506
   PubMed Web of Science ®Google Scholar
• Desai NR, Kohli P, Giugliano RP, et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation 2013;128(9):962-9
   PubMed Web of Science ®Google Scholar
• Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007;356(2):148-56
   PubMed Web of Science ®Google Scholar
• Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013;381(9860):40-6
   PubMed Web of Science ®Google Scholar
• Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008;5(8):497-505
   PubMedGoogle Scholar
• Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010;362(10):906-16
   PubMed Web of Science ®Google Scholar
• Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One 2010;5(12):e14328
   PubMed Web of Science ®Google Scholar
• Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75(5):898-915
   PubMed Web of Science ®Google Scholar
• Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol 2008;52(2):124-31
   PubMed Web of Science ®Google Scholar
• Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365(24):2255-67
   PubMed Web of Science ®Google Scholar
• Albers JJ, Slee A, O’Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 2013;62(17):1575-9
   PubMed Web of Science ®Google Scholar
• Besseling J, Hovingh GK, Stroes ES. Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promises. Neth J Med 2013;71(3):118-22
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9719):998-1006
   PubMed Web of Science ®Google Scholar
• Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012;126(19):2283-92
   PubMed Web of Science ®Google Scholar
• McGowan MP, Tardif JC, Ceska R, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One 2012;7(11):e49006
   PubMed Web of Science ®Google Scholar
• Thomas GS, Cromwell WC, Ali S, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2013;62(23):2178-84
   PubMed Web of Science ®Google Scholar
• Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2012;33(9):1142-9
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31(23):2844-53
   PubMed Web of Science ®Google Scholar
• Merki E, Graham M, Taleb A, et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol 2011;57(15):1611-21
   PubMed Web of Science ®Google Scholar
• Thompson GR, Barbir M, Davies D, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010;208(2):317-21
   PubMed Web of Science ®Google Scholar
• Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009;6(3):229-39
   PubMedGoogle Scholar
• Leebmann J, Roeseler E, Julius U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013;128(24):2567-76
   PubMed Web of Science ®Google Scholar
• Safarova MS, Ezhov MV, Afanasieva OI, et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl 2013;14(1):93-9
   PubMed Web of Science ®Google Scholar
• Chennamsetty I, Claudel T, Kostner KM, et al. Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest 2011;121(9):3724-34
   PubMed Web of Science ®Google Scholar
• Chennamsetty I, Claudel T, Kostner KM, et al. FGF19 signaling cascade suppresses APOA gene expression. Arterioscler Thromb Vasc Biol 2012;32(5):1220-7
   PubMed Web of Science ®Google Scholar
• Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose-response study of the effects of cholestyramine in hypercholesterolaemia. Atherosclerosis 1982;44(1):61-71
   PubMed Web of Science ®Google Scholar
• Dobs AS, Prasad M, Goldberg A, et al. Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs. Cardiovasc Drugs Ther 1995;9(5):677-84
   PubMed Web of Science ®Google Scholar
• Akaike M, Azuma H, Kagawa A, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002;48(9):1454-9
   PubMed Web of Science ®Google Scholar
• Kyutoku M, Nakagami H, Koriyama H, et al. Inhibition of neointima formation through DNA vaccination for apolipoprotein(a): a new therapeutic strategy for lipoprotein(a). Sci Rep 2013;3:1600
   PubMed Web of Science ®Google Scholar
• Edelstein C, Pfaffinger D, Hinman J, et al. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 2003;278(52):52841-7
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 2010;56(12):946-55
   PubMed Web of Science ®Google Scholar
• van Dijk RA, Kolodgie F, Ravandi A, et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res 2012;53(12):2773-90
   PubMed Web of Science ®Google Scholar
• Leibundgut G, Scipione C, Yin H, et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res 2013;54(10):2815-30
   PubMed Web of Science ®Google Scholar
• Brown WV, Ballantyne CM, Jones PH, Marcovina S. Management of Lp(a). J Clin Lipidol 2010;4(4):240-7
   PubMed Web of Science ®Google Scholar